SEC Tracker
Get the app

Pfizer PFE

Pfizer names Cecile Guegan CFO

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Cecile Guegan elected CFO effective November 1, 2026
  2. Annual base salary of $1.3M, target cash incentive of $1.3M
  3. Guegan has 25+ years in pharma finance, joined Pfizer in 2009

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Pfizer files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 3 claims matched the filing text.

Not found in the filing text

  • For the quarter ended September 27, 2026, PFIZER INC reported revenue of $16.6 billion and net income of $3.2 billion.
  • The company's gross margin was 75.7% and net margin was 19.6% for the quarter.
  • Revenue decreased by 0.4% compared to the same period a year earlier.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  2. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  3. Merck MRK public float $198.1B, Jun 30, 2025
  4. Regeneron Pharmaceuticals REGN public float $54.8B, Jun 30, 2025
  5. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025